This week's new post on the CLL Society website http://cllsociety.org
is an update of the data from trials with ibrutinib in treatment-naïve and relapsed patients presented by Dr. Byrd from an interview done at the CRC (CLL Research Consortium) meeting in San Diego in April 2015.
Dr. Byrd presents the long-term data from patients having received almost three years of treatment with ibrutinib for chronic lymphocytic leukemia. The data are increasingly positive, however there are still concerns with relapse, especially in those with genetic instability such as those with 17p deletion or a complex karyotype.
Still the news is good.
For my take away points, and Dr. Byrd's upbeat message from the short part 2 of our interview at the CRC meeting, please here.
I am part of this cohort as I am now 40+ months on ibrutinib with both 17p deletion or a complex karyotype, so this data is something I watch closely.
We are all this together
Volunteer Medical Director of the CLL Society
Labels: Chronic lymphocytic leukemia, CLL, Dr. Byrd, ibrutinib